曲美他嗪对2型糖尿病病人心脏功能的影响

目的:探讨曲美他嗪对2型糖尿病病人心脏功能的影响。方法:60例2型糖尿病病人随机分为2组, 每组30例。均予常规治疗控制血糖,治疗组另予曲美他嗪20 mg,po,tid,疗程12 wk。2组于治疗前后分别测定空腹血糖(FBG)、游离脂肪酸(FFAs),心脏B超测量左室射血分数(EF)、左室短轴缩短百分率(FS)、左室等容舒张时间(IVRT)、E波与A波峰值速度比值(E／A)、E峰与A峰流速时间积分的比值(EVI／AVI)等指标。结果:2组治疗后,FBG均下降,EF,FS,IVRT,E／A和EVI／AVI均增加,与治疗前比较,差异有显著或非常显著意义(P<0．05,P<0．01)。FFAs虽有上升,但与治疗前相比无显著差异(P>0．05)。其中治疗组IVRT,E／A,EVI／ AVI上升幅度明显高于对照组(P<0．01),而FBS,FFAs,EF和FS的变化2组间无显著差异(P>0．05)。结论:曲美他嗪可能通过优化糖尿病心肌能量代谢,从而改善2型糖尿病病人心脏舒张功能。

Effect of trimetazidine on cardiac function of patients with type 2 diabetes mellitus

AIM: To investigate effect of trimetazidine on cardiac function of patients with type 2 diabetes mellitus. METHODS: Sixty patients with type 2 diabetes mellitus were divided into two groups randomly. All patients in both groups received routine therapy in order to have high blood glucose under control. In addition, patients in the treatment group were given trimetazidine 20 mg,tid,for 12 wk. Fasting blood glucose(FBG) ,free fatty acids (FFAs),and cardiac function (including EF,FS,IVRT,E/A,EVI/AVI,et al)were measured before and after the treatment. RESULTS: After treatment, FBG decreased significantly in both groups while EF, FS, IVRT, E/A and EVI/AVI increased significantly in comparing with those before the treatment (P < 0.05, P < 0.01). Both FFAs increased, but showed no significant difference in comparing with those before the treatment (P > 0.05). The values of IVRT, E/A, EVI/AVI in treatment group were obviously higher than those in the control group (P < 0.01), while no significant difference existed in FBG, FFAs, EF and FS between the two groups (P > 0.05). CONCLUSION: Diastole cardiac function in patients with type 2 diabetes mellitus could be improved by trimetazidine, probably by its benefits on myocardial energy metabolism.